Novel molecular biomarkers in kidney diseases: bridging the gap between early detection and clinical implementation
Journal of Pharmacy and Pharmacology · 2026
DOI: 10.1093/jpp/rgaf096 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Pharmacy and Pharmacology, 2026. Verfasst von Bhavana Bagdaram Choudhary und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Birla Institute of Technology and Science Pilani, Pilani Campus, Vidya Vihar, Pilani, Rajasthan 333031, India. Hauptthemen laut MEDLINE: Biomarkers, Kidney Diseases. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 104 Literaturangaben.
Abstract (Originalsprache)
Background
Kidney diseases affect over 850 million people globally and are a significant cause of morbidity and mortality. Traditional biomarkers like serum creatinine, blood urea nitrogen, and proteinuria have limited sensitivity and specificity, often detecting damage only after substantial renal function loss. Even U.S. Food and Drug Administration (FDA)-approved biomarkers, such as kidney injury molecule-1, neutrophil gelatinase-associated lipocalin, and cystatin C, have limitations because their levels can be influenced by inflammation, infections, or disease stage. There is an urgent need for reliable, non-invasive biomarkers for early diagnosis and treatment guidance.
Objective
This review provides an updated overview of emerging biomarkers for early detection and monitoring of kidney diseases (acute kidney injury, chronic kidney disease, diabetic kidney disease, polycystic kidney disease, lupus nephritis, renal cell carcinoma).
Methods
A comprehensive literature review focused on studies from the past decade on urine and blood-based biomarkers that reflect key pathological processes, including inflammation, tubular injury, fibrosis, and immune activation.
Results
Promising biomarkers include collectrin, olfactomedin 4, activin A, follistatin, USP18, galectin-3, fetuin-A, sestrin-2, podocalyxin, copeptin, anti-C1q, p-cresol glucuronide, serum CD206, lncRNAs, and miRNAs.
Conclusions
These biomarkers may enhance early diagnosis, enable personalized therapy, and improve kidney disease outcomes. Their integration into clinical practice may bridge the gap between early detection and effective intervention, potentially improving long-term outcomes in patients with kidney disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Birla Institute of Technology and Science Pilani, Pilani Campus, Vidya Vihar, Pilani, Rajasthan 333031, India.
ORCID-Profile: Anil Bhanudas Gaikwad
Zitieren
APA
Choudhary, B. B., Puri, B., & Gaikwad, A. B. (2026). Novel molecular biomarkers in kidney diseases: bridging the gap between early detection and clinical implementation. Journal of Pharmacy and Pharmacology. https://doi.org/10.1093/jpp/rgaf096
Vancouver
Choudhary BB, Puri B, Gaikwad AB. Novel molecular biomarkers in kidney diseases: bridging the gap between early detection and clinical implementation. Journal of Pharmacy and Pharmacology. 2026. doi:10.1093/jpp/rgaf096
BibTeX
@article{Choudhary2026,
author = {Choudhary, Bhavana Bagdaram and Puri, Bhupendra and Gaikwad, Anil Bhanudas},
title = {Novel molecular biomarkers in kidney diseases: bridging the gap between early detection and clinical implementation},
journal = {Journal of Pharmacy and Pharmacology},
year = {2026},
doi = {10.1093/jpp/rgaf096}
}
EUVIMED